Jack Cassel
All right. I guess the music is off and that is our queue. So thank you all for joining us today for our conversation. We’ll kick things off and then you’ll do most of talking to tell this incredible story for us. But for everybody, I’m Jack Cassel, Senior Vice President with NASDAQ. And I’m excited for our discussion today with the Chief Executive Officer, Kim Kelderman; and Chief Financial Officer, Jim Hippel, for Bio-Techne.
So maybe for the audience, let’s level set with just an overview on the business.
Kim Kelderman
CEO, President & Director
Thank you, Jack, first of all, for having us and hosting the conference. We’re very excited, and we are 15 years in the making. So Bio-Techne itself, 50 years old. However, we say old, the core business that we have created over these 50 years is 7,000 proteins and 400,000 antibodies, basically lego blocks for any life science tools, laboratory that wants to make progress. So we’re deeply entrenched in everything research really.
But over the last 10 years or so, we’ve really doubled down on trying to utilize these components into faster-growing application areas. And we have 4 application areas that we focused on. One of them is cell therapy. Basically, everything to do with growing cells, immune cells or regenerative cells to cure diseases. And for that, you need all these core components I mentioned earlier, and we also have a bioreactor to help grow these cells processes.
The second area we focused on is proteomics, proteomic analysis. We know that has been
